Side effects, cost, supply, target: four reasons with four trajectories

Cost is the modal reason for stopping and the least represented in the clinical literature. Real-world analyses of pharmacy claims consistently find that a large minority of people who start one of these drugs for weight management are no longer filling prescriptions a year later, with discontinuation concentrated in the first three months and strongly patterned by coverage rather than by clinical response. That is an economics finding sitting inside a clinical question, and this publication reports it in both departments.

Resuming after an interruption is a fresh escalation

This is the most practically consequential item in the whole subject and the one least often stated in advance. Gastrointestinal tolerability to these agents develops over weeks of continued exposure and decays when exposure is removed. After four weeks without the drug, plasma concentrations are a small fraction of steady state and the tolerability accommodation has substantially reset. Resuming at the previous maintenance dose therefore presents the system with an exposure step it has not experienced for a month.

The clinical convention — resume at a lower dose and re-escalate — follows from the pharmacokinetics rather than from caution.¹ Product labelling for several agents in the class advises consideration of re-initiation at a lower dose after an extended interruption, and the threshold at which this applies differs between products, which is a detail worth checking against the specific label rather than a general rule.

The shortage period demonstrated the consequence of ignoring this at scale. Large numbers of people lost access for six to ten weeks, resumed where they had left off, and experienced nausea and vomiting considerably worse than during their original escalation. It was predictable, it was predicted by anybody who had read the label carefully, and it was almost never communicated.

Cost is the modal reason, and it is missing from the clinical literature

Analyses of pharmacy claims consistently find that persistence with these agents for weight management is poor relative to their efficacy, with a large minority of people no longer filling prescriptions within a year of starting and discontinuation concentrated in the first three months.² The pattern tracks coverage, deductible reset timing and cash price far more closely than it tracks clinical response, which is the signature of an economic rather than a therapeutic discontinuation.

Almost none of this appears in the clinical literature on withdrawal. The trials studied people who stopped because a protocol told them to, with the drug supplied free, in a population willing to be randomised. That is close to the opposite of the situation in which most discontinuation actually occurs: unplanned, unsupervised, at a time set by an insurer or a price rise rather than by a clinical assessment, and frequently without anybody being told it has happened.

The Journal reports discontinuation in both this department and The Ledger for that reason. The clinical trajectory after stopping is a Patient Notes question; why people stop is an economics question; and the two literatures currently do not speak to one another at all.

The supply interruption as a clinical event

A supply gap is a discontinuation with no notice, no plan and no taper. It differs from every other route to stopping in that it is imposed on both the patient and the prescriber, its duration is unknown at the outset, and it frequently ends as abruptly as it began. The shortage listings of recent years produced these events at population scale, and they have not been studied as a clinical exposure.

Three features make them distinctive. The patient cannot plan a maintenance strategy around an interruption of unknown length. Substitution — to a different agent, a different dose, or a compounded preparation — happens under time pressure and often without a dose-equivalence basis, since no head-to-head equivalence data exists between agents in this class. And the resumption problem described above applies in full, because the gaps were typically long enough to reset tolerability.

The Journal reported these events as they occurred and continues to think they represent the largest uncontrolled interruption experiment in the history of the class. What nobody collected was outcome data: how much weight was regained during the gaps, how many people never resumed, and what happened to the glycaemic control of those taking the drugs for diabetes rather than for weight.

When the indication is not weight

The withdrawal question changes shape when the drug was prescribed for something other than weight. In the cardiovascular outcome trial of semaglutide in overweight and obesity without diabetes, the reduction in major adverse cardiovascular events emerged over years of continued treatment, and the trial provides no information about what happens to that benefit on cessation.³ The same applies to the renal outcome data in chronic kidney disease with type 2 diabetes, where the effect on kidney disease progression was measured over a median of several years of treatment.⁴

There is no reason to expect an outcome benefit that accrues over years to persist after the exposure ends, and no trial has tested it. For a person taking the drug for glycaemic control, stopping has an immediate and measurable consequence in HbA1c over the following three months. For a person taking it for cardiovascular or renal risk, stopping has no measurable short-term consequence at all, which makes the decision harder rather than easier.

This is the situation in which the Journal thinks the withdrawal-trial coverage has done the most damage. Framing discontinuation as a weight question invites a person taking the drug for kidney disease to reason about it in the wrong currency entirely.

Restarting after a long gap: what to expect

Restarting after months away is well tolerated in general and the response is broadly reproducible: people who lost weight on an agent and stopped generally lose weight again on resuming, at a similar rate. There is no established phenomenon of a diminished second response in this class, and the withdrawal trials that re-offered treatment after their observation periods did not report one.

Three practical features recur. Escalation has to start again from a low dose for tolerability reasons, which means several weeks before the previous maintenance exposure is re-established. The nausea of a second escalation is frequently reported as worse than the first, for which the Journal has seen no mechanistic explanation and would not rule out reporting bias. And the weight trajectory on restarting begins from wherever the person now is, so a second course is a longer project than the first if regain was substantial.

None of this constitutes advice about whether to restart, which is a clinical decision. It is offered as a description of what the trial reports and the correspondence describe, and readers should note that no trial has been designed to study re-initiation as its primary question.

How the Journal reports a regain figure

Four things accompany every regain number in these pages. Which withdrawal design it comes from, because an off-treatment extension and a randomised placebo switch are different experiments. Whether the lifestyle intervention continued in the arm being described. What the denominator is — regain as a percentage of body weight, as a percentage of the weight lost, or as a final position relative to original baseline, three quantities that are routinely quoted interchangeably. And the follow-up duration, because the regain curve decelerates and a figure at six months is not a figure at a year.

The third of those is where most of the misreporting happens. A statement that participants regained two-thirds is a proportion of loss; a statement that they regained eleven per cent is a proportion of body weight; a statement that they finished 5.6 per cent below baseline is a final position. All three can describe the same arm and they are not interchangeable.

Where a source we are quoting has not stated its denominator, we say that rather than inferring it. Readers who find a regain figure in these pages without its design and its denominator have found an error, and the standards desk would like to hear about it at standards@compoundjournal.com.

The Journal will keep pressing the maintenance question, because it is answerable, cheap to answer, and unanswered for reasons that are commercial rather than scientific. A dose-reduction trial in this class would cost a small fraction of a pivotal programme and would change the treatment of millions of people. Its absence is the single most conspicuous gap in the literature this department covers.